Clemedi AG

Give the right antibiotics: by combining DNA sequencing with artificial intelligence, the Clemedi platform delivers comprehehnsive next day results that allow to choose the optimal antibiotic therapy.

Our first application on the Clemedi platforn, Tuberculini, for the diagnosis of tuberculosis has received CE-IVD mark and is available on the EU market. We will generate further clinical evidence with selected partner by the end of the year.

If no action is taken, drug-resistant diseases could cause 10 million deaths each year by 2050 and damage to the economy as catastrophic as the 2008-2009 global financial crisis. The main driver is the current overuse and misuse of antibiotics, which can be reduced by targeted diagnostics.

Clemedi has developed a platform to recommend the optimal antibiotic therapy by screening bactrial DNA for antibiotics resistance markers and predicting response to antibiotics using machine learning.

We sell all reagents necessary to perform the laboratory steps of our product as well as the analysis software charging a fee per test.

Mass Challenge Switzerland
Venturekick